Image 2_Serum creatinine-to-cystatin C ratio and 1-year mortality risk in advanced breast cancer patients: a multicenter retrospective cohort study.tif
Background<p>Muscle wasting and sarcopenia in advanced breast cancer correlates with poor outcomes. The serum creatinine-to-cystatin C ratio (CCR) is a potential muscle mass biomarker, but its prognostic value in advanced breast cancer is unclear.</p>Methods<p>This multicenter retr...
Bewaard in:
| Hoofdauteur: | |
|---|---|
| Andere auteurs: | , , , , , , , , |
| Gepubliceerd in: |
2025
|
| Onderwerpen: | |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|
| _version_ | 1849927624262942720 |
|---|---|
| author | Huijie Deng (5664421) |
| author2 | Jiacheng Yang (4867897) Guanyu Zheng (602277) Biyao Zhang (3160059) Yuzhou Wang (600730) Yuye Wu (22381971) Shufen Mo (21743543) Shengchao Huang (22686392) Yuanqi Zhang (18483375) Lixia Li (407712) |
| author2_role | author author author author author author author author author |
| author_facet | Huijie Deng (5664421) Jiacheng Yang (4867897) Guanyu Zheng (602277) Biyao Zhang (3160059) Yuzhou Wang (600730) Yuye Wu (22381971) Shufen Mo (21743543) Shengchao Huang (22686392) Yuanqi Zhang (18483375) Lixia Li (407712) |
| author_role | author |
| dc.creator.none.fl_str_mv | Huijie Deng (5664421) Jiacheng Yang (4867897) Guanyu Zheng (602277) Biyao Zhang (3160059) Yuzhou Wang (600730) Yuye Wu (22381971) Shufen Mo (21743543) Shengchao Huang (22686392) Yuanqi Zhang (18483375) Lixia Li (407712) |
| dc.date.none.fl_str_mv | 2025-11-26T05:15:20Z |
| dc.identifier.none.fl_str_mv | 10.3389/fnut.2025.1688477.s002 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/figure/Image_2_Serum_creatinine-to-cystatin_C_ratio_and_1-year_mortality_risk_in_advanced_breast_cancer_patients_a_multicenter_retrospective_cohort_study_tif/30717752 |
| dc.rights.none.fl_str_mv | CC BY 4.0 info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Clinical and Sports Nutrition breast cancer creatinine cystatin C creatinine–cystatin C muscle mass sarcopenia mortality |
| dc.title.none.fl_str_mv | Image 2_Serum creatinine-to-cystatin C ratio and 1-year mortality risk in advanced breast cancer patients: a multicenter retrospective cohort study.tif |
| dc.type.none.fl_str_mv | Image Figure info:eu-repo/semantics/publishedVersion image |
| description | Background<p>Muscle wasting and sarcopenia in advanced breast cancer correlates with poor outcomes. The serum creatinine-to-cystatin C ratio (CCR) is a potential muscle mass biomarker, but its prognostic value in advanced breast cancer is unclear.</p>Methods<p>This multicenter retrospective cohort study included 465 patients with stage III-IV breast cancer (2018–2023) receiving standard treatment. The creatinine-cystatin C ratio (CCR) was calculated based on baseline serum markers. The primary endpoint was the 1-year all-cause mortality rate, as assessed through medical records and follow-up. A multivariate Cox regression model was used to analyze the relationship between CCR and mortality, along with restricted cubic spline, Kaplan–Meier survival analysis, ROC curve, and subgroup analysis.</p>Results<p>This study enrolled a total of 465 patients with stage III-IV breast cancer, with a median age of 52.0 (interquartile range [IQR], 47.0–60.0)years and a median creatinine-cystatin C ratio (CCR) of 1.0 (IQR, 0.8–1.2). The 1-year mortality rate among all patients was 26.2% (122/465), with a mortality rate of 18.1% (52/288) for stage III patients and 39.5% (70/177) for stage IV patients. Multivariate Cox proportional hazards regression analysis showed a significant negative association between CCR and 1-year all-cause mortality in breast cancer patients (adjusted HR = 0.68, 95% CI: 0.63–0.74, p < 0.001). Compared with the lowest quartile group (Q1), the highest quartile group (Q4) had a mortality risk reduction of 94% (HR = 0.06, 95% CI: 0.03–0.14, p < 0.001). Restricted cubic spline analysis confirmed a linear negative association between the two (P for non-linear = 0.178). The Kaplan–Meier survival curves showed a significantly higher 1-year all-cause mortality in the Q1 group (p < 0.0001). The area under the curve (AUC) for predicting 1-year mortality was 0.802 (95% CI: 0.756–0.849). Subgroup analysis revealed a significant interaction between CCR and chemotherapy (p = 0.013) and clinical stage (p < 0.001), while the negative correlation persisted in other subgroups. Sensitivity analysis using unadjusted data yielded consistent results (Q4 HR = 0.06, 95% CI: 0.02–0.14), confirming the robustness of the study conclusions.</p>Conclusion<p>The serum creatinine-cystatin C ratio is an independent predictor of 1-year mortality risk in advanced breast cancer, with higher levels associated with significantly reduced mortality.</p> |
| eu_rights_str_mv | openAccess |
| id | Manara_626ede31a949391fd77218355feca452 |
| identifier_str_mv | 10.3389/fnut.2025.1688477.s002 |
| network_acronym_str | Manara |
| network_name_str | ManaraRepo |
| oai_identifier_str | oai:figshare.com:article/30717752 |
| publishDate | 2025 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY 4.0 |
| spelling | Image 2_Serum creatinine-to-cystatin C ratio and 1-year mortality risk in advanced breast cancer patients: a multicenter retrospective cohort study.tifHuijie Deng (5664421)Jiacheng Yang (4867897)Guanyu Zheng (602277)Biyao Zhang (3160059)Yuzhou Wang (600730)Yuye Wu (22381971)Shufen Mo (21743543)Shengchao Huang (22686392)Yuanqi Zhang (18483375)Lixia Li (407712)Clinical and Sports Nutritionbreast cancercreatininecystatin Ccreatinine–cystatin Cmuscle masssarcopeniamortalityBackground<p>Muscle wasting and sarcopenia in advanced breast cancer correlates with poor outcomes. The serum creatinine-to-cystatin C ratio (CCR) is a potential muscle mass biomarker, but its prognostic value in advanced breast cancer is unclear.</p>Methods<p>This multicenter retrospective cohort study included 465 patients with stage III-IV breast cancer (2018–2023) receiving standard treatment. The creatinine-cystatin C ratio (CCR) was calculated based on baseline serum markers. The primary endpoint was the 1-year all-cause mortality rate, as assessed through medical records and follow-up. A multivariate Cox regression model was used to analyze the relationship between CCR and mortality, along with restricted cubic spline, Kaplan–Meier survival analysis, ROC curve, and subgroup analysis.</p>Results<p>This study enrolled a total of 465 patients with stage III-IV breast cancer, with a median age of 52.0 (interquartile range [IQR], 47.0–60.0)years and a median creatinine-cystatin C ratio (CCR) of 1.0 (IQR, 0.8–1.2). The 1-year mortality rate among all patients was 26.2% (122/465), with a mortality rate of 18.1% (52/288) for stage III patients and 39.5% (70/177) for stage IV patients. Multivariate Cox proportional hazards regression analysis showed a significant negative association between CCR and 1-year all-cause mortality in breast cancer patients (adjusted HR = 0.68, 95% CI: 0.63–0.74, p < 0.001). Compared with the lowest quartile group (Q1), the highest quartile group (Q4) had a mortality risk reduction of 94% (HR = 0.06, 95% CI: 0.03–0.14, p < 0.001). Restricted cubic spline analysis confirmed a linear negative association between the two (P for non-linear = 0.178). The Kaplan–Meier survival curves showed a significantly higher 1-year all-cause mortality in the Q1 group (p < 0.0001). The area under the curve (AUC) for predicting 1-year mortality was 0.802 (95% CI: 0.756–0.849). Subgroup analysis revealed a significant interaction between CCR and chemotherapy (p = 0.013) and clinical stage (p < 0.001), while the negative correlation persisted in other subgroups. Sensitivity analysis using unadjusted data yielded consistent results (Q4 HR = 0.06, 95% CI: 0.02–0.14), confirming the robustness of the study conclusions.</p>Conclusion<p>The serum creatinine-cystatin C ratio is an independent predictor of 1-year mortality risk in advanced breast cancer, with higher levels associated with significantly reduced mortality.</p>2025-11-26T05:15:20ZImageFigureinfo:eu-repo/semantics/publishedVersionimage10.3389/fnut.2025.1688477.s002https://figshare.com/articles/figure/Image_2_Serum_creatinine-to-cystatin_C_ratio_and_1-year_mortality_risk_in_advanced_breast_cancer_patients_a_multicenter_retrospective_cohort_study_tif/30717752CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/307177522025-11-26T05:15:20Z |
| spellingShingle | Image 2_Serum creatinine-to-cystatin C ratio and 1-year mortality risk in advanced breast cancer patients: a multicenter retrospective cohort study.tif Huijie Deng (5664421) Clinical and Sports Nutrition breast cancer creatinine cystatin C creatinine–cystatin C muscle mass sarcopenia mortality |
| status_str | publishedVersion |
| title | Image 2_Serum creatinine-to-cystatin C ratio and 1-year mortality risk in advanced breast cancer patients: a multicenter retrospective cohort study.tif |
| title_full | Image 2_Serum creatinine-to-cystatin C ratio and 1-year mortality risk in advanced breast cancer patients: a multicenter retrospective cohort study.tif |
| title_fullStr | Image 2_Serum creatinine-to-cystatin C ratio and 1-year mortality risk in advanced breast cancer patients: a multicenter retrospective cohort study.tif |
| title_full_unstemmed | Image 2_Serum creatinine-to-cystatin C ratio and 1-year mortality risk in advanced breast cancer patients: a multicenter retrospective cohort study.tif |
| title_short | Image 2_Serum creatinine-to-cystatin C ratio and 1-year mortality risk in advanced breast cancer patients: a multicenter retrospective cohort study.tif |
| title_sort | Image 2_Serum creatinine-to-cystatin C ratio and 1-year mortality risk in advanced breast cancer patients: a multicenter retrospective cohort study.tif |
| topic | Clinical and Sports Nutrition breast cancer creatinine cystatin C creatinine–cystatin C muscle mass sarcopenia mortality |